ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 568

Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals

Laura Hunt1, Sahar Musaad1,2, John Stephenson3, Becki Burn2, Isao Matsuura1, Kulveer Mankia1, Jackie L. Nam1 and Paul Emery1, 1NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Microbiology, Calderdale & Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom, 3Department Health Sciences, University of Huddersfield, Huddersfield, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ACPA, biomarkers and rheumatoid arthritis, pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Whilst the exact aetiology of rheumatoid arthritis (RA) remains unclear, current concepts suggest an environmental link with possible microbial triggers.  Studying individuals at-risk of RA allows a unique opportunity to explore possible relationships.  Furthermore, the identification of predictors of progression from at-risk to RA is of great clinical utility.   Triggering receptor expressed on myeloid cells (TREM) modulates the innate immune response by either amplifying or dampening the toll like receptors (TLR) induced signalling1.  Given the upstream nature of soluble-TREM (sTREM), and its close proximity to TLR in innate immune response to microbial triggers, we hypothesis that sTREM could be one of the first indicators of progression to RA.   

Methods: sTREM was measured using Human TREM-1 Quantikine ELISA (R&D Systems, Minneapolis) in 32 at-risk individuals; 16 of whom progressed (ACPA+ Prog) and 16 whom did not (ACPA+ NProg), and 16 early RA (ERA) patients.  The ACPA+ cohort had no evidence of ultrasound synovitis at baseline. Binary logistic regression models were conducted on at-risk patients. Model discrimination was assessed using classification plots and the area under the ROC curve. An optimum cut-off for the test variable, plus associated sensitivity and specificity achieved, were also determined. Further analyses were conducted on the same sample augmented with ERA patients, to assess the correlation between TREM, CRP and CCP titre values in this group; and on ERA patients only, to assess the correlation between TREM and DAS28 values in this group.  

Results: Duration of follow-up was 0 to 133 months, mean duration of 36 months (SD 31.2).  Mean time to RA diagnosis in those that progressed was 11.5 months (SD 14.3).   

Variable

Group

 
ERA ACPA+ Prog ACPA+ NProg All
Gender (n (%))       Female 9 (56.2%) 10 (62.5%) 11 (68.7%) 30 (62.5%)
Age (years) (mean (SD)) 55.2 (14.8) 53.8 (13.6) 53.9 (10.3) 54.3 (12.7)
TREM IU (mean (SD)) 539.3 (207.9) 711.0 (292.0) 405.0 (230.4)* 554.8 (271.9)
CRP ng/l (mean (SD)) 40.3 (61.0) 4.77 (5.61)* 4.53 (6.59)** 18.6 (41.6)
CCP IU (mean (SD)) 92.4 (127.1) 174.9 (108.8) 132.5 (135.1) 133.3 (126.1)
*n=15; **n=10        

A binary logistic regression model found that TREM was significantly associated with progression (p=0.009). The OR of 1.006 (95% CI 1.002 to 1.011) indicated that at best estimate, the odds of progression increased by 0.6% with each increase of 1 unit of TREM.  The model classified 80.6% of cases correctly, with 12 out of 16 (75.0%) of ACPA+ P cases and 13 out of 15 (86.7%) of ACPA+ NP cases correctly classified. The area under the ROC curve was 0.825 (95% CI 0.674 to 0.976).  Optimum combinations of sensitivity (81.3%) and specificity (80.0%) were obtained from a cut-off TREM value of 521.3 units.  There were no substantive correlations between TREM, CRP values and CCP values.

Conclusion: In this first assessment high level of sTREM is significantly associated with disease progression in at-risk individuals.  Furthermore, higher sTREM values are associated with greater odds of progression. It has potential to offer insights regarding disease pathogenesis and warrants further research.  References: 1. Bouchon A et al, Nature 2001  


Disclosure: L. Hunt, None; S. Musaad, None; J. Stephenson, None; B. Burn, None; I. Matsuura, None; K. Mankia, None; J. L. Nam, None; P. Emery, Pfizer,MSD,Abbvie,BMS,UCB,Roche,Novartis,Samsung, Sandoz, Eli Lillyand Company, 5.

To cite this abstract in AMA style:

Hunt L, Musaad S, Stephenson J, Burn B, Matsuura I, Mankia K, Nam JL, Emery P. Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/triggering-receptor-expressed-on-myeloid-cells-trem-as-a-novel-indicator-of-disease-progression-in-at-risk-individuals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/triggering-receptor-expressed-on-myeloid-cells-trem-as-a-novel-indicator-of-disease-progression-in-at-risk-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology